Altshuler Shaham’s Celldex Therapeutics CLDX Stock Holding History

Altshuler Shaham’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-32,000	Closed	-$863K	–	468
2022 Q2	$863K	Hold	32,000	–	–	0.01%	84
2022 Q1	$1.09M	Sell	32,000 -14,500	-31%	-$464K	0.01%	144
2021 Q4	$1.8M	Hold	46,500	–	–	0.02%	140
2021 Q3	$2.52M	Hold	46,500	–	–	0.02%	124
2021 Q2	$1.55M	Hold	46,500	–	–	0.01%	154
2021 Q1	$958K	Hold	46,500	–	–	0.01%	100
2020 Q4	$815K	Hold	46,500	–	–	0.02%	80
2020 Q3	$690K	Buy	+46,500	New	+$545K	0.02%	89

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Altshuler Shaham's CLDX Position: Q3 2022 in Review

Altshuler Shaham sold out of Celldex Therapeutics (CLDX) in Q3 2022, closing a stake of 32,000 shares — an estimated $863K sold.

Altshuler Shaham first reported a position in CLDX in Q3 2020 and held it in 8 quarters. The position peaked at $2.52M in Q3 2021. 158 funds tracked by Wall St. Rank hold CLDX as of Q3 2022.

Altshuler Shaham reported no remaining Celldex Therapeutics position as of Q3 2022 after selling out during the quarter.
Altshuler Shaham sold 32,000 Celldex Therapeutics shares in Q3 2022, an estimated $863K.
Altshuler Shaham first reported a position in Celldex Therapeutics in Q3 2020 and held it in 8 quarters.
Altshuler Shaham's Celldex Therapeutics position peaked at $2.52M in Q3 2021.
158 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2022.

Based on Altshuler Shaham's 13F filing for Q3 2022, filed 14 Nov 2022.